CYP2D6 and Alzheimer disease: In the case of AD, most studies coincide in that the APOE and CYP2D6 genes are the most influential genes for the pharmacogenetic outcome, representing pathogenic (APOE) and metabolic (CYPD2) genes associated with the therapeutic response to conventional treatments [2,3,4,6,7,19,125,127,133].